PCSK9 and cardiovascular disorder: Finally, we assessed the performance of single-AAV ABEs in mice by using them to install base edits associated with decreased cardiovascular disease risk, resulting in efficient editing (averaging 50%) of human PCSK9, mouse Pcsk9 and mouse Angptl3 in bulk liver at a range of clinically relevant doses with concomitant substantial reduction in circulating target protein, total cholesterol and triglycerides.